Note 12 - Subsequent Events (Details Textual) - HM43239 [Member] - Subsequent Event [Member] $ in Millions |
Nov. 04, 2021
USD ($)
shares
|
|---|---|
| Asset Acquisition, Consideration Transferred, Total | $ 12.5 |
| Payments to Acquire Productive Assets, Total | 5.0 |
| Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable | $ 7.5 |
| Asset Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares | 3,235,548 |
| Clinical Development and Global Regulatory Milestone, First Indication | $ 64.5 |
| Clinical Development and Global Regulatory Milestone, Second Indication | 34.0 |
| Clinical Development and Global Regulatory Milestone, Third Indication | 29.0 |
| Global Sales Milestone | $ 280.0 |
| X | ||||||||||
- Definition Number of shares of equity interests issued or issuable to acquire asset. No definition available.
|
| X | ||||||||||
- Definition Represents the target clinical development and global regulatory milestones for the first indication. No definition available.
|
| X | ||||||||||
- Definition Represents the target clinical development and global regulatory milestones for the second indication. No definition available.
|
| X | ||||||||||
- Definition Represents the target clinical development and global regulatory milestones for the third indication. No definition available.
|
| X | ||||||||||
- Definition Represents the target global sales milestone. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|